首页> Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation> Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.

Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.

导出原文传递

翻译打印收藏纠错

第一作者： Zachariah,DeFilipp

第一单位： Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts.

作者： Zachariah,DeFilipp ^[1] ; Shuli,Li ^[2] ; Maria E,Kempner ^[1] ; Jami,Brown ^[1] ; Candice,Del Rio ^[1] ; Betsy,Valles ^[1] ; Chrisa,Hunnewell ^[1] ; Meredith,Saylor ^[1] ; Julie,Vanderklish ^[1] ; Bimalangshu R,Dey ^[1] ; Areej,El-Jawahri ^[1] ; Steven L,McAfee ^[1] ; Thomas R,Spitzer ^[1] ; Yi-Bin,Chen ^[3]

作者单位： Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts. ^[1] Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. ^[2] Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: ychen6@partners.org. ^[3]

关键词 Allogeneic hematopoietic cell transplantation Brentuximab vedotin Chronic graft-versus-host disease Phase I study